Novartis AG
Rapamycin derivatives

Abstract:

The disclosure relates to compounds of formula (I) ##STR00001## and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.